SavedAdd your journal

Journals / İstanbul Medical Journal / 2017 / Cilt: 18 - Sayı: 3

The Expressions of Cancer Stem Cell Markers and Non- classical HLA antigens in Breast Tumors

Meme Tümörlerinde Kanser Kök Hücre Belirteçleri ve Non-classic HLA Antijenlerinin Ekspresyonları

Rabia Bilge Özgül ÖZDEMİR
Alper Tunga ÖZDEMİR
Gürkan YİĞİTTÜRK
Cengiz KIRMAZ
Kamile KURT
Fatih OLTULU
Pages
128–134
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: We detected that the significantly increased expressions of especially Nanog (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: There is a strong relationship between the cancer stem cells (CSCs) and poor prognosis, metastasis and recurrence.
📊
Key Findings & Data:Methods: We immunohistochemically evaluated that the expressions of cluster of differentiation (CD) 44, CD133, Homeobox protein Nanog, octamerbinding transcription factor (Oct) 3/4, HLA-G and HLA-E in the advanced stage breast cancer tissues (n=10) and the non-malignant breast biopsies (n=10).
💡
Conclusion & Impact:Results: We detected that the significantly increased expressions of especially Nanog (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: There is a strong relationship between the cancer stem cells (CSCs) and poor prognosis, metastasis and recurrence. In addition to this CSCs are resistant to chemotherapy and radiotherapy. Therefore, current treatment approaches may be ineffective to elimination of CSCs. The tumor cells have various adaptations for escaping from immune cells. The human leukocyte antigen (HLA) -G, which expressions restricted with fetal tissues and HLA-E are kind of tumor immune evasive adaptations. In this study, we aimed to investigate the relationship between the CSCs and immune evasive adaptations of breast tumors. Methods: We immunohistochemically evaluated that the expressions of cluster of differentiation (CD) 44, CD133, Homeobox protein Nanog, octamerbinding transcription factor (Oct) 3/4, HLA-G and HLA-E in the advanced stage breast cancer tissues (n=10) and the non-malignant breast biopsies (n=10). Results: We detected that the significantly increased expressions of especially Nanog (p

Özet

Amaç: Kanser kök hücreler (KKH) ile kötü prognoz, metastaz ve rekürens arasında güçlü bir ilişki vardır. Buna ek olarak KKH'ler kemoterapi ve radyoterapiye dirençli hücrelerdir. Bu nedenle mevcut tedavi yaklaşımları KKH'lerin eliminasyonunda yetersiz kalabilmektedir. Tümör hücrelerinin immün hücrelerden kaçabilmek için çeşitli adaptasyonları bulunur. Ekspresyonları fetal dokularla kısıtlı olan human leukocyte antigen (HLA) G ve ayrıca HLA-E, tümör immün evazif adaptasyonlardır. Bu çalışmada meme tümörlerinde KKH ve immün evazif adaptasyonlar arasındaki ilişkiyi incelemeyi amaçladık. Yöntemler: İleri evre meme kanseri dokuları (n=10) ile malign olmayan meme tümörü dokularında (n=10) immünohistokimyasal olarak cluster of differentiation (CD)44, CD133, Homeobox protein Nanog, octamer-binding transcription factor (Oct)3/4, HLA-G ve HLA-E ekspresyonlarını değerlendirdik. Bulgular: Özellikle Nanog (p

🔖

Cite This Article

ÖZDEMİR, R. B. Ö., ÖZDEMİR, A. T., YİĞİTTÜRK, G., KIRMAZ, C., KURT, K., OLTULU, F. (2022). The Expressions of Cancer Stem Cell Markers and Non- classical HLA antigens in Breast Tumors. İstanbul Medical Journal, Cilt: 18 - Sayı: 3, 128–134. https://ajindex.com/articles/552061

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Shaheen S, Ahmed M, Lorenzi F, Nateri AS. Spheroid-Formation (Colonosphere) Assay for in Vitro Assessment and Expansion of Stem Cells in Colon Cancer. Stem Cell Rev 2016
  2. [CrossRef] 2. Schmohl JU, Vallera DA. CD133, Selectively Targeting the Root of Cancer. Toxins 2016
  3. [CrossRef] 3. Sodja E, Rijavec M, Koren A, Sadikov A, Korošec P, Cufer T. The prognostic value of whole blood SOX2, NANOG and OCT4 mRNA expression in advanced small-cell lung cancer. Radiol Oncol 2016
  4. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CHM, Jones DL, et al. Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006
  5. [CrossRef] 5. Peitzsch C, Kurth I, Kunz-Schughart L, Baumann M, Dubrovska A. Discovery of the cancer stem cell related determinants of radioresistance. Radiother Oncol 2013
  6. [CrossRef] 6. Mia-Jan K, Munkhdelger J, Lee M-R, Ji S-Y, Kang TY, Choi E, et al. Expression of CD133 in neuroendocrine neoplasms of the digestive tract: a detailed immunohistochemical analysis. Tohoku J Exp Med 2013
  7. [CrossRef] 7. Amini S, Fathi F, Mobalegi J, Sofimajidpour H, Ghadimi T. The expressions of stem cell markers: Oct4, Nanog, Sox2, nucleostemin, Bmi, Zfx, Tcl1, Tbx3, Dppa4, and Esrrb in bladder, colon, and prostate cancer, and certain cancer cell lines. Anat Cell Biol 2014
  8. [CrossRef] 8. Anders CK, Abramson V, Tan T, Dent R. The evolution of triple-negative breast cancer: from biology to novel therapeutics. Am Soc Clin Oncol Educ Book 2016
  9. [CrossRef] 9. Mirzania M. Approach to the triple negative breast cancer in new drugs area. Int J Hematol Oncol Stem Cell Res 2016
  10. Reim F, Dombrowski Y, Ritter C, Buttmann M, Häusler S, Ossadnik M, et al. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/ CD24low/HER2low breast cancer stem cells. Cancer Res 2009
  11. [CrossRef] 11. Diessner J, Bruttel V, Becker K, Pawlik M, Stein R, Häusler S, et al. Targeting breast cancer stem cells with HER2-specific antibodies and natural killer cells. Am J Cancer Res 2013
  12. Comber JD, Philip R. MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines. Ther Adv Vaccines 2014
  13. [CrossRef] 13. Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune e